ASH 2022 | Updated results from the MOMENTUM study assessing the efficacy of momelotinib in MF
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, shares some updated results from the MOMENTUM study (NCT04075305), which is comparing the efficacy of momelotinib to danazol in anemic and symptomatic patients with myelofibrosis (MF). Dr Gerds highlights that patients treated with momelotinib were found to experience durable responses with minimal toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kratos Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Imago BioSciences: Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Accurate Pharmaceuticals: Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Morphosys/Constellation: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; PharmaEssentia: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
